This opportunity is no longer accepting applications.
grant PAR-22-047
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
This grant offers funding for the early development stages of new drugs that aim to prevent, slow, or treat Alzheimer's disease. The focus is on small-molecule and biologic drug candidates, covering pre-clinical work and early Phase I clinical trials.
The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and b…
Funding Source
Agency: National Institutes of Health
Program: SBIR
Dates
Opportunity Released: November 15, 2021
Open for Submission: November 15, 2021
Submission Deadline: November 5, 2024
Application Window Closes: November 5, 2024
Documents
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers